| アブストラクト | BackgroundCardiovascular medications are commonly prescribed to older adults; however, their potential association with cognitive decline remains poorly understood.ObjectiveThis study aimed to systematically evaluate the relationship between cardiovascular drugs and the risk of dementia.Methods(1) A retrospective disproportionality analysis of the FDA Adverse Event Reporting System data, accessed via OpenVigil 2.1, which examined 97 cardiovascular drugs across 14 therapeutic categories in patients aged >/=60 years, and (2) a literature review of case-reports of drug-induced cognitive impairment.ResultsOf the 97 drugs analyzed, disproportionate reporting signals (indicating more frequent reporting than expected by chance) were identified for 38 (39.2%) across four types of dementia: dementia (13.4%), Alzheimer's disease (16.5%), vascular dementia (18.6%), and dementia with Lewy-bodies (6.2%). ACE inhibitors exhibited the highest signal rate (75.0%). Thirteen case-reports were identified, primarily involving statins (53.8%). Discontinuation of the drug resulted in cognitive improvement in 12/13 cases.ConclusionsThis study identifies disproportionate dementia-related adverse event reporting for nearly 40% of cardiovascular drugs examined, with ACE inhibitors and ARBs showing the highest signal rates. However, these findings are preliminary and require validation through future pharmacoepidemiological studies. |
| ジャーナル名 | Journal of geriatric psychiatry and neurology |
| Pubmed追加日 | 2026/1/3 |
| 投稿者 | Syed, Jehath; Potdar, Amruta; Chalasani, Sri Harsha |
| 組織名 | Department of Pharmaceutical Sciences, School of Health Sciences and Technology,;Dr. Vishwanath Karad MIT World Peace University, Pune, India.;Clinical Surveillance Scientist, Global Patient Safety, Eli Lilly and Company,;Bengaluru, India.;Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher;Education and Research, Mysuru, India. |
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41482885/ |